Intellia Therapeutics (NTLA) Interest & Investment Income (2016 - 2026)
Intellia Therapeutics (NTLA) reported Interest & Investment Income of $5.2 million for Q1 2026, down 39.5% year-over-year from $8.6 million in Q1 2025, and down 19.63% on a QoQ basis from $6.5 million in Q4 2025.
Intellia Therapeutics (NTLA) has 11 years of Interest & Investment Income data on file, last reported at $5.2 million in Q1 2026.
- Quarterly Interest & Investment Income fell 39.5% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.8 million (down 41.07% YoY) and the FY2025 annual result came in at $29.2 million, down 38.93% from the prior year.
- Interest & Investment Income fell to $5.2 million in Q1 2026 per NTLA's latest filing, from $6.5 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $12.7 million in Q3 2023 and bottomed at $540000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $8.6 million (2025), against an average of $8.3 million.
- The widest annual swing landed in 2023, when Interest & Investment Income surged 2118.52%; it then tumbled 44.61% in 2025.
- Tracing NTLA's Interest & Investment Income over 5 years: stood at $5.4 million in 2022, then soared by 132.7% to $12.5 million in 2023, then slipped by 14.67% to $10.6 million in 2024, then plunged by 39.08% to $6.5 million in 2025, then decreased by 19.63% to $5.2 million in 2026.
- Per Business Quant, the three latest NTLA Interest & Investment Income figures stand at $5.2 million (Q1 2026), $6.5 million (Q4 2025), and $6.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 5.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.21 Mn |
| Dec 31, 2025 | 6.48 Mn |
| Sep 30, 2025 | 6.71 Mn |
| Jun 30, 2025 | 7.40 Mn |
| Mar 31, 2025 | 8.60 Mn |
| Dec 31, 2024 | 10.63 Mn |
| Sep 30, 2024 | 12.12 Mn |
| Jun 30, 2024 | 12.42 Mn |
| Mar 31, 2024 | 12.63 Mn |
| Dec 31, 2023 | 12.46 Mn |
| Sep 30, 2023 | 12.74 Mn |
| Jun 30, 2023 | 12.65 Mn |
| Mar 31, 2023 | 11.98 Mn |
| Dec 31, 2022 | 5.35 Mn |
| Sep 30, 2022 | 1.95 Mn |
| Jun 30, 2022 | 703,000.00 |
| Mar 31, 2022 | 540,000.00 |
| Dec 31, 2021 | 503,000.00 |
| Sep 30, 2021 | 349,000.00 |
| Jun 30, 2021 | 211,000.00 |
| Mar 31, 2021 | 220,000.00 |
| Dec 31, 2020 | 207,000.00 |
| Sep 30, 2020 | 262,000.00 |
| Jun 30, 2020 | 641,000.00 |
| Mar 31, 2020 | 1.24 Mn |
| Dec 31, 2019 | 1.50 Mn |
| Sep 30, 2019 | 1.69 Mn |
| Jun 30, 2019 | 1.78 Mn |
| Mar 31, 2019 | 1.87 Mn |
| Dec 31, 2018 | 1.68 Mn |
| Sep 30, 2018 | 1.40 Mn |
| Jun 30, 2018 | 1.38 Mn |
| Mar 31, 2018 | 1.07 Mn |
| Dec 31, 2017 | 752,000.00 |
| Sep 30, 2017 | 519,000.00 |
| Jun 30, 2017 | 424,000.00 |
| Mar 31, 2017 | 317,000.00 |
| Dec 31, 2016 | 259,000.00 |
| Sep 30, 2016 | 215,000.00 |
| Jun 30, 2016 | 46,000.00 |
| Mar 31, 2016 | 5,000.00 |